Thermo Fisher Scientific has signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.

Formed through the merger of Florida Biologix and Brammer Biopharmaceuticals in 2016, Brammer Bio is a contract development and manufacturing organisation (CDMO) owned by Ampersand Capital Partners.

The company is focused on clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

It is also engaged in process and analytical development, and provides regulatory support to large pharmaceutical and biotech firms for the development of new drugs.

Brammer Bio is expected to generate $250m in revenue this year.

Acquisition of the CDMO is intended to bolster Thermo Fisher Scientific’s pharma services business.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thermo Fisher Scientific president and CEO Marc Casper said: “Gene therapy is an area of increasing focus for our customers and is fast-evolving given its potential to treat a range of genetic disorders.

“The combination of Brammer Bio’s viral vector capabilities with our GMP production expertise and proprietary bioprocessing and cell culture technologies uniquely positions us to partner with our customers to drive the evolution of this incredibly fast-growing market.”

“Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes.”

Brammer Bio employs nearly 600 people at its primary locations in Massachusetts and Florida in the US. The Massachusetts operations include a 66,000ft2 Phase III and commercial CGMP viral vector manufacturing facility and an adjacent 49,000ft2 warehouse and distribution centre.

The company’s 80,000ft2 early clinical campus in Florida comprises three buildings with a process development and analytical development facility.

The Brammer Bio CGMP facility in Florida is intended for viral vector processing to support early phase clinical trials.

Brammer Bio president and CEO Mark Bamforth and chief scientific officer Richard Snyder said: “Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes, and we’re excited to join Thermo Fisher to take our business to the next level.”

Subject to customary closing conditions, the acquisition is expected to be completed by the second quarter of this year.

After the closing of the deal, Brammer Bio will be integrated into Thermo Fisher’s pharma services business within its Laboratory Products and Services unit.